Regenerative Medicine Weekly Trend Line

Home > Regenerative Medicine Weekly Trend Line > Regenerative Medicine Weekly Trend Line

Regenerative Medicine Weekly Trend Line

July 31st, 2011 Henry McCusker Leave a comment Go to comments

Shares of regenerative medicine stem cell companies are reacting to visibility and sentiment issues as stocks are acting as a thermometer of investor emotion.

The key to anticipate share pricing will be the respective CASH positions at the end of Q2/11.

The Dow posted its worst weekly loss of the year on Friday as angry and frustrated investors looked anywhere for cover from the political crisis in Washington. Unfortunately, our universe is overly affected! Congressional failure to find any common ground on debt-ceiling legislation as well as a horrible GDP report shaved about 500 points off the blue-chip index this week. Confidence is dissolving more rapidly than the data and markets would suggest. US stocks extended a multisession losing streak Friday, sending the Dow industrials and the S&P 500 Index to their worst weeks in more than a year. The Dow lost 4.2% for the week and 2.2% for July. The S&P 500 lost 3.9% for the week and 2.2% for the month. The NASDAQ dropped 3.6% for the week and 0.6% for the month.

At the end of the week (7/29/11), the NASDAQ was DOWN -8.97 (-0.36%) to 2756.38. The Dow was DOWN -96.87 (-0.79) to 12,143.24.

Universe shares “CONTINUE TO BE HAMMERED” from lows of the past weeks and month. Earnings season is upon us … as RegMed companies announce their latest LPS’ (Loss per share). Luckily, debt brinksmanship “heightens” overall market sentiment and investor attitudes drawing attention elsewhere. (Last week close, 7/29/11 = LW)

Advancers (5):

Athersys (ATHX) up +$0.07 (+2.62%) to $2.74 (LW $2.85):
BioHeart (BHRT.OB) up +$0.013 (+10.48%) to $0.137 (LW:$0.25);
Fibrocell Sciences (OTC: FCSC) up +$0.015 (+2.29%) to $0.67 (LW:$0.678 );
Opexa (OPXA) up +$0.21 (+16.28%) to $1.50 (LW $1.42);
NeoStem (AMEX: NBS) up +$0.01 (+1.19%) to $0.85 <post offering/acquisition>(LW $1.05);
Pluristem (PSTI) up +0.05 (+1.48%) to $3.43 (LW $3.33);

Decliners (15):

Aastrom (ASTM) down -0.03 (-1.18%) to $2.52 (LW $2.75);
Advanced Cell Technology (OTC: ACTC) down -$0.003 (-1.85%) to $0.185 (LW $0.194);
BioMimetic (BMTI) down -$0.12 (-3.02%) to $3.86 (LW $4.38);
BioTime (AMEX: BTX) down -$0.19 (-3.75%) to $4.88 (LW $5.25);
Brainstorm (BCLI.OB) down -$0.005 (-1.11%) to $0.445 (LW $0.52);
Cytori (CYTX) down -0.04 (-0.92%) to $4.33 (LW $4.72);
ImmunoCellar Therapeutics (IMUC) down -$0.07 (-3.26%) to $2.08 (LW $2.25);
International Stem Cell (ISCOE.OB) down -$0.04 (-4.17%) to $0.92 (LW $0.89);
Geron (GERN) down -0.04 (-1.03%) to $3.85 (LW $4.16);
Osiris (OSIR) down -$0.09 (-1.24%) to $7.15 (LW $7.80);
Neuralstem (AMEX:CUR) down $0.01 (-0.87%) to $1.14 (LW $1.38);
ReNeuron Group (RENE.L) down -$0.01 (-0.10%) to $5.02 (LW $4.70);
StemCells (STEMD) down -$0.21 (-5.43%) to $3.66 <1 to 10 reverse > (LW $3.85); and
ThermoGenesis (KOOL) down -$0.06 (-2.94%) to $1.98 (LW $2.09).
Tengion (TNGN) down -$0.02 (-1.22%) to $1.23 (LW $1.38).

The Bottom Line: Declining stocks versus advancers (15 versus 5, this week 11 versus 8 last week as compared to previous week’s 6 versus 14 followed by 11 versus 6 highlights diminished sentiment issues in indicators.

This weeks biggest winners (that is a misnomer) of the regenerative medicine universe close were Opexa (OPXA) up +$0.21 (+16.28%) to $1.50; Athersys (ATHX) up +$0.07 (+2.62%) to $2.74; Pluristem (PSTI) up +0.05 (+1.48%) to $3.43.

Weekly Highlights:

Referenced announcements: worth reviewing …

This Week’s Treatise: The “UGLY” budget fight is spooking the markets …

What a difference a couple of months make … earnings season is upon us … the key to share pricing in the next few months will be the respective CASH positions at the end of Q2/11.

The second key element this week … was the dismissal of Shirley versus Sebelius federal stem cell research law suit concerning funding of embryonic stem cell research. US District Judge Royce Lamberth had issued an injunction to block the research while the case continued. But the appeals court overturned his injunction. Lamberth said in his ruling Wednesday, 7/27/11 that he was bound by the higher court’s analysis and ruled in favor of the administration’s motion to dismiss the case.

The trend is “hardly” our friend when a 500-point weekly loss in the Dow leaves investors wondering. Overall stocks (macro) fell 4% but, they are still only 3% off their 3 year highs. We should feel … lucky that order flow even downward was orderly minus the drama of the federal debt ceiling fight.

There is a lot of skepticism about the forthcoming earnings concerning risk and expectation. The risk is the market open to future fund raising; the expectation is who needs it … and at what price?

Reiterating from last week, companies must be more transparent in overcoming ANY questions re sustainability, viability of development scenarios and clinical trial probabilities … Positioning their regulatory initiatives must be competitively defined and modeled to articulate differences and comparisons … in therapies and approach.

My bellwethers remain – (Ranked in order): NeoStem (AMEX: NBS), Cytori (CYTX), Osiris (OSIR) … Athersys (ATHX) and BioTime (AMEX: BTX) …

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.